LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

LLY

903

-1.58%↓

JNJ

235.46

-0.93%↓

ABBV

204.23

-0.92%↓

NVS

145.89

-1.52%↓

AZN

183.37

-2.88%↓

Strona główna・Stock List・Ascendis Pharma A-S ADR

Ascendis Pharma A-S ADR

Closed

SectorHealthcare

220.5 -1.05

Buy Sell

Overview

Share price change

24h

Current

Min

220.49

Max

225.84

Key metrics
By Trading Economics
Income	28M -33M
Sales	32M 245M
Profit margin	-13.56
Employees	1,189
EBITDA	68M 15M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+31.01% upside

Dividends
By Dow Jones
Next Earnings	30 kwi 2026

Market Stats
By TradingEconomics
Market Cap	618M 14B
Previous open	221.55
Previous close	220.5

News Sentiment

By Acuity

54%

46%

284 / 350 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

157.66 / 167.29 Support & Resistance

Ascendis Pharma A-S ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

20 mar 2026, 17:19 UTC

Major News Events

Chubb to Assume Risk, Issue Policies for $20 Billion Strait of Hormuz Insurance Facility

20 mar 2026, 16:56 UTC

Major News Events

Week Ahead for FX, Bonds: PMI Data to Show Middle East War's Impact on Sentiment

20 mar 2026, 16:56 UTC

Major News Events

Week Ahead for FX, Bonds: PMI Data to Show Middle -2-

20 mar 2026, 16:45 UTC

Major News Events

The Week in Oil: U.S. Seeks to Ease Concerns Over War But Supply Risks Mount

20 mar 2026, 16:22 UTC

Major News Events

NYMEX Overview: Petroleum Futures Rise, Leaving Most Contracts on Track for Solid Weekly Gains -- OPIS

20 mar 2026, 20:50 UTC

Market Talk

Major News Events

Basic Materials Roundup: Market Talk

20 mar 2026, 20:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Health Care Roundup: Market Talk

20 mar 2026, 19:55 UTC

Market Talk

Major News Events

Brent Crude Closes Out Volatile Week Higher -- Market Talk

20 mar 2026, 19:28 UTC

Market Talk

Major News Events

Natural Gas Falls as Traders Sell Ahead of the Weekend -- Market Talk

20 mar 2026, 19:28 UTC

Acquisitions, Mergers, Takeovers

Ecolab Buys CoolIT Systems for $4.75 Billion. It's All About AI for the Struggling Stock. -- Barrons.com

20 mar 2026, 18:39 UTC

Market Talk

Gold Settles With Largest Weekly Dollar Decline on Record -- Market Talk

20 mar 2026, 18:31 UTC

Acquisitions, Mergers, Takeovers

Honeywell Announces Pricing of Debt Tender Offers >HON

20 mar 2026, 18:19 UTC

Acquisitions, Mergers, Takeovers

Why Mayo and Soap No Longer Mix for Unilever -- Update

20 mar 2026, 18:15 UTC

Market Talk

iMarkets May Be Wrong in Pricing for Canadian Rate Increases -- Market Talk

20 mar 2026, 17:57 UTC

Market Talk

U.S. Oil Rig Count Inches Up -- Market Talk

20 mar 2026, 17:04 UTC

Major News Events

Chubb to Assume Risk, Issue Policies for $20B Strait of Hormuz Insurance Facility

20 mar 2026, 16:20 UTC

Market Talk

Major News Events

Basic Materials Roundup: Market Talk

20 mar 2026, 16:20 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Health Care Roundup: Market Talk

20 mar 2026, 15:40 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Unilever, McCormick Deal Makes Strategic Sense, But Risk Remains -- Market Talk

20 mar 2026, 15:30 UTC

Earnings

Gemini Space Station's Earnings 'Better Than Feared.' Can They Save the Stock? -- Barrons.com

20 mar 2026, 15:26 UTC

Market Talk

Earnings

Major News Events

Lands' End: War Impacts Weighing on Some European Consumers -- Market Talk

20 mar 2026, 15:26 UTC

Acquisitions, Mergers, Takeovers

Why Mayo and Soap No Longer Mix for Unilever -- WSJ

20 mar 2026, 15:25 UTC

Market Talk

Gilt Selloff Shows Vulnerability of U.K.'s Economy -- Market Talk

20 mar 2026, 15:19 UTC

Market Talk

Major News Events

UBS Raises Oil Price Forecast as Middle East Conflict Escalates -- Market Talk

20 mar 2026, 14:58 UTC

Major News Events

Chevron Jumps Into Top 20 Most Valuable U.S. Companies. The Iran War's Other Big Stock Movers. -- Barrons.com

20 mar 2026, 14:55 UTC

Market Talk

Major News Events

Gold Lower as Speculative Pullback Extends -- Market Talk

20 mar 2026, 14:54 UTC

Acquisitions, Mergers, Takeovers

Ecolab Buys CoolIT Systems for $4.75 Billion. It's All About AI for the Struggling Stock. -- Barrons.com

20 mar 2026, 14:53 UTC

Acquisitions, Mergers, Takeovers

Unilever, McCormick Deal Would Create a New Condiment King -- WSJ

20 mar 2026, 14:46 UTC

Market Talk

U.K. Government Bonds Selloff More Pronounced Than Peers -- Market Talk

20 mar 2026, 14:45 UTC

Market Talk

Major News Events

Oil Price Forecasts For 2026-27 Raised at UBS -- Market Talk

Peer Comparison

Price change

Ascendis Pharma A-S ADR Forecast

Price Target

By TipRanks

31.01% upside

12 Months Forecast

Average 293.23 USD 31.01%

High 342 USD

Low 255 USD

Based on 13 Wall Street analysts offering 12 month price targets forAscendis Pharma A-S ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

13 ratings

Buy

Hold

Sell

Based on 13 analysts giving stock ratings to Ascendis Pharma A-S ADR - Dist in the past 3 months.

Technical Score

By Trading Central

157.66 / 167.29Support & Resistance

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

All events are bullish.

Sentiment

By Acuity

284 / 350 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Ascendis Pharma A-S ADR

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.